Literature DB >> 10933074

Applications of magnetic resonance in model systems: cancer therapeutics.

J L Evelhoch1, R J Gillies, G S Karczmar, J A Koutcher, R J Maxwell, O Nalcioglu, N Raghunand, S M Ronen, B D Ross, H M Swartz.   

Abstract

The lack of information regarding the metabolism and pathophysiology of individual tumors limits, in part, both the development of new anti-cancer therapies and the optimal implementation of currently available treatments. Magnetic resonance [MR, including magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and electron paramagnetic resonance (EPR)] provides a powerful tool to assess many aspects of tumor metabolism and pathophysiology. Moreover, since this information can be obtained nondestructively, pre-clinical results from cellular or animal models are often easily translated into the clinic. This review presents selected examples of how MR has been used to identify metabolic changes associated with apoptosis, detect therapeutic response prior to a change in tumor volume, optimize the combination of metabolic inhibitors with chemotherapy and/or radiation, characterize and exploit the influence of tumor pH on the effectiveness of chemotherapy, characterize tumor reoxygenation and the effects of modifiers of tumor oxygenation in individual tumors, image transgene expression and assess the efficacy of gene therapy. These examples provide an overview of several of the areas in which cellular and animal model studies using MR have contributed to our understanding of the effects of treatment on tumor metabolism and pathophysiology and the importance of tumor metabolism and pathophysiology as determinants of therapeutic response.

Entities:  

Mesh:

Year:  2000        PMID: 10933074      PMCID: PMC1531871          DOI: 10.1038/sj.neo.7900078

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  104 in total

1.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?

Authors:  C K Kuhl; P Mielcareck; S Klaschik; C Leutner; E Wardelmann; J Gieseke; H H Schild
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

3.  Selective depletion of tumor ATP by 2-deoxyglucose and insulin, detected by 31P magnetic resonance spectroscopy.

Authors:  G S Karczmar; J M Arbeit; B J Toy; A Speder; M W Weiner
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

4.  Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro.

Authors:  J C Street; A A Alfieri; J A Koutcher
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

5.  Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.

Authors:  J D Moyer; R E Handschumacher
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

Review 6.  Reoxygenation and repopulation in irradiated tumors.

Authors:  R F Kallman
Journal:  Front Radiat Ther Oncol       Date:  1988

7.  Potentiation of a three drug chemotherapy regimen by radiation.

Authors:  J A Koutcher; A A Alfieri; R L Stolfi; M L Devitt; J R Colofiore; L D Nord; D S Martin
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

8.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

9.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

10.  Effect of cyclophosphamide on the pathophysiology of RIF-1 solid tumors.

Authors:  P G Braunschweiger
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

View more
  42 in total

1.  Noninvasive real-time imaging of apoptosis.

Authors:  Bharathi Laxman; Daniel E Hall; Mahaveer Swaroop Bhojani; Daniel A Hamstra; Thomas L Chenevert; Brian D Ross; Alnawaz Rehemtulla
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-10       Impact factor: 11.205

2.  The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.

Authors:  Bradford A Moffat; Thomas L Chenevert; Charles R Meyer; Paul E McKeever; Daniel E Hall; Benjamin A Hoff; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

Review 3.  Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods.

Authors:  Markus Rudin; Martin Rausch; Markus Stoeckli
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

4.  Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

Authors:  Simon P Robinson; Tammy L Kalber; Franklyn A Howe; Dominick J O McIntyre; John R Griffiths; David C Blakey; Lynsey Whittaker; Anderson J Ryan; John C Waterton
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

5.  Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

Authors:  Bénédicte F Jordan; Matthew Runquist; Natarajan Raghunand; Amanda Baker; Ryan Williams; Lynn Kirkpatrick; Garth Powis; Robert J Gillies
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

6.  Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Hyunki Kim; Karri D Folks; Lingling Guo; Jeffery C Sellers; Naomi S Fineberg; Cecil R Stockard; William E Grizzle; Donald J Buchsbaum; Desiree E Morgan; James F George; Kurt R Zinn
Journal:  Mol Imaging       Date:  2011-06       Impact factor: 4.488

7.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

Authors:  G H Fisher; S L Wellen; D Klimstra; J M Lenczowski; J W Tichelaar; M J Lizak; J A Whitsett; A Koretsky; H E Varmus
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

8.  Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.

Authors:  Gabriel Ramirez; Ashley R Proctor; Ki Won Jung; Tong Tong Wu; Songfeng Han; Russell R Adams; Jingxuan Ren; Daniel K Byun; Kelley S Madden; Edward B Brown; Thomas H Foster; Parisa Farzam; Turgut Durduran; Regine Choe
Journal:  Biomed Opt Express       Date:  2016-08-24       Impact factor: 3.732

9.  Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy.

Authors:  Regine Choe; Turgut Durduran
Journal:  IEEE J Sel Top Quantum Electron       Date:  2011-12-02       Impact factor: 4.544

10.  Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study.

Authors:  J Klawitter; N Anderson; J Klawitter; U Christians; D Leibfritz; S G Eckhardt; N J Serkova
Journal:  Br J Cancer       Date:  2009-03-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.